S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
66,000% upside on tiny biotech? (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
66,000% upside on tiny biotech? (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
66,000% upside on tiny biotech? (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
66,000% upside on tiny biotech? (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
NASDAQ:CRDF

Cardiff Oncology (CRDF) Stock Forecast, Price & News

$1.66
+0.04 (+2.47%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$1.58
$1.68
50-Day Range
$1.37
$1.95
52-Week Range
$1.17
$3.41
Volume
126,600 shs
Average Volume
216,449 shs
Market Capitalization
$74.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Cardiff Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
381.9% Upside
$8.00 Price Target
Short Interest
Healthy
1.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Cardiff Oncology in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.09) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

416th out of 1,010 stocks

Biological Products, Except Diagnostic Industry

61st out of 169 stocks


CRDF stock logo

About Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Receive CRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

CRDF Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Cardiff City
Disturbing Truth About Biden's New Program To Seize Your Cash
A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Championship side Cardiff hire Lamouchi as new boss
See More Headlines
Receive CRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

CRDF Company Calendar

Last Earnings
5/04/2023
Today
5/29/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRDF
Fax
N/A
Employees
22
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+381.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-38,700,000.00
Net Margins
-9,862.78%
Pretax Margin
-9,856.71%

Debt

Sales & Book Value

Annual Sales
$390,000.00
Book Value
$2.16 per share

Miscellaneous

Free Float
43,113,000
Market Cap
$74.17 million
Optionable
Not Optionable
Beta
1.74

Social Links


Key Executives

  • Mark ErlanderMark Erlander
    Chief Executive Officer & Director
  • Vicki KelemenVicki Kelemen
    Chief Operating Officer
  • James E. LevineJames E. Levine
    Chief Financial Officer
  • Tod Smeal
    Chief Scientific Officer
  • Fairooz Kabbinavar
    Chief Medical Officer













CRDF Stock - Frequently Asked Questions

Should I buy or sell Cardiff Oncology stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDF shares.
View CRDF analyst ratings
or view top-rated stocks.

What is Cardiff Oncology's stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month price targets for Cardiff Oncology's shares. Their CRDF share price forecasts range from $5.00 to $14.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 381.9% from the stock's current price.
View analysts price targets for CRDF
or view top-rated stocks among Wall Street analysts.

How have CRDF shares performed in 2023?

Cardiff Oncology's stock was trading at $1.40 on January 1st, 2023. Since then, CRDF shares have increased by 18.6% and is now trading at $1.66.
View the best growth stocks for 2023 here
.

Are investors shorting Cardiff Oncology?

Cardiff Oncology saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 542,300 shares, a decline of 12.1% from the April 30th total of 616,900 shares. Based on an average daily volume of 198,500 shares, the short-interest ratio is currently 2.7 days.
View Cardiff Oncology's Short Interest
.

When is Cardiff Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CRDF earnings forecast
.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.08 million. Cardiff Oncology had a negative net margin of 9,862.78% and a negative trailing twelve-month return on equity of 35.70%.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

What is Cardiff Oncology's stock symbol?

Cardiff Oncology trades on the NASDAQ under the ticker symbol "CRDF."

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.70%), Citigroup Inc. (1.46%), Assenagon Asset Management S.A. (0.88%), Renaissance Technologies LLC (0.74%), Two Sigma Advisers LP (0.32%) and Blair William & Co. IL (0.29%). Insiders that own company stock include Gary W Pace, James E Levine, John P Brancaccio, Lale White, Mark Erlander, Renee P Tannenbaum, Rodney S Markin and Vicki Kelemen.
View institutional ownership trends
.

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiff Oncology's stock price today?

One share of CRDF stock can currently be purchased for approximately $1.66.

How much money does Cardiff Oncology make?

Cardiff Oncology (NASDAQ:CRDF) has a market capitalization of $74.17 million and generates $390,000.00 in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How can I contact Cardiff Oncology?

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The official website for the company is cardiffoncology.com. The company can be reached via phone at (858) 952-7570 or via email at ir@cardiffoncology.com.

This page (NASDAQ:CRDF) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -